A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
AI-Driven CT Imaging Predicts Cardiac Events in Large UK Cohort
An AI tool analyzing CCTA images can predict future cardiovascular events and death in patients with suspected stable coronary artery disease.
•EurekAlert
AI Tool from UCLA Targets Undiagnosed Alzheimer's and Diagnostic Disparity
UCLA researchers developed an AI model using EHR data to better detect undiagnosed Alzheimer's disease, especially in underrepresented groups.
•EurekAlert
AI Multimodal Models Improve Breast Cancer Recurrence Risk Prediction
Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.